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Knowledge of Efficacy of Treatments in Lung Cancer Is Not
Enough, Their Clinical Effectiveness Should Also Be Known
Ikuo Sekine, MD, PhD,* Minoru Takada, MD,† Hiroshi Nokihara, MD, PhD,*
Seiichiro Yamamoto PhD,‡ and Tomohide Tamura, MD*
The benefits established in efficacy trials, usually randomized,
controlled trials conducted under highly controlled circumstances
with maximized internal validity, can frequently not be demonstrated in
clinical practice at the community level. Effectiveness trials are tools to
evaluate the applicability of a treatment in a wider setting with maxi-
mized external validity, to observe uncommon adverse events, and to
identify factors influencing the main outcomes and risks. Important
areas in relation to lung cancer treatment that will benefit from effec-
tiveness trials include gefitinib monotherapy and bevacizumab therapy
combined with cytotoxic chemotherapy for advanced non-small cell
lung cancer. These therapies were found to produce life-threatening
nonhematologic toxicity at a high incidence of up to 5%; however, the
risk factors for these toxicities have not yet been fully established.
Effectiveness trials of adjuvant chemotherapy after surgery with long-
term follow-up are also important to obtain reliable information as to
secondary malignancy and noncancer-related deaths. Development of
an infrastructure for effectiveness trials is crucial because of the neces-
sity to deal with large numbers of patients, sometimes as many as
10,000 patients, from many hospitals. The extensive research time
involved and the considerable cost of these trials may be reduced with
the use of Internet resources. Effectiveness trials are a fundamental step
toward bridging the gap between clinical research and clinical practice
and effectively implementing new therapies in clinical practice.
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The current paradigm in medical practice is “evidence-based medicine,” which has been defined as the “consci-
entious, explicit and judicious use of current best evidence in
making decisions about the care of individual patients.”1
Randomized, controlled trials (RCTs) are considered the best
evidence of efficacy because they employ an experimental
design that reduces bias and confounding. The tacit assump-
tion is that the potential benefits of new therapies as shown in
RCTs will also be observed in clinical practice. The benefits
established in RCTs, however, have been scarcely demon-
strated in clinical practice in the community. The response to
and compliance with a treatment can be highly dependent on
factors such as the patient characteristics, the methods of
application of the treatment, and the treatment setting. RCTs
are usually performed on a homogeneous study population
from which clinically complex patients such as the elderly
and infirm patients are generally excluded for the sake of
study feasibility. Evidence from such highly selected popu-
lations, therefore, cannot easily be generalized to nonselected
patients.2,3
SUBGROUP ANALYSES AND META-ANALYSES
Subgroup analyses are an approach to enable the most
effective use of treatment in routine practice. These analyses
may be useful to compare the treatment effects and the risk of
adverse events between subgroups in relation to patient char-
acteristics, leading to identification of subgroups of patients
most likely to benefit.4 In this case, the limitations are lack of
power due to the smaller number of patients involved, the
limits of nonrandomized comparison, and false-positive re-
sults from the multiplicity of subgroups, and, therefore,
validating the results of such analysis is needed in future
trials.4 Meta-analyses of RCTs aim to integrate the effects of
treatment across trials in such a way that they can be trans-
lated into practice. Comparing the outcomes of patient sub-
groups within a meta-analysis may be more useful than a
subgroup analysis within a trial, although analyses of indi-
vidual patient data from trials are necessary.5 In addition, a
meta-analysis has a better external validity than an RCT if the
benefit of a treatment was shown on RCTs performed in
different settings, in different patient populations, and in
different areas of the world.6
These methods can evaluate heterogeneity of results
from subgroups of patients registered in RCTs, but cannot
evaluate patients excluded from these trials, such as patients
with comorbidities. Thus, another type of large trial that
includes these patients, called effectiveness trials, is needed
to apply the treatment in the real world of clinical practice.
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EFFICACY AND EFFECTIVENESS TRIALS
Efficacy and effectiveness are terms that are rarely used
correctly and are often interchanged.7,8 Efficacy is the true
biological effect of a treatment under the ideal conditions of
an investigation, whereas effectiveness is the beneficial effect
observed when the treatment is used in clinical practice in the
community at large, which is influenced by many aspects,
including the patient characteristics and the social health
system. Efficacy trials, also called explanatory trials, are
primarily developmental tools used to make inferences re-
lated to the treatment modality in question (Table 1).9 The
maximum potential benefits that can be derived from a
treatment are estimated under ideal, highly controlled circum-
stances in clinical research settings, usually in RCTs, to
establish a causal link between the treatment and the primary
outcome with maximized internal validity. Efficacy trials are
conducted in a homogeneous group of patients who are
carefully selected based on strict eligibility criteria. The
sample size is large enough to have adequate power to detect
significant effects. Patients are randomly allocated to either
the treatment under investigation or a control standard treat-
ment to equalize the distribution of potential confounding
factors. In efficacy trials, the treatment is delivered by highly
skilled, rigorously trained, and closely supervised specialists,
using standardized, manual-based protocols under close mon-
itoring to ensure fidelity or delivery of treatment as intended
in teaching hospitals.
On the other hand, effectiveness trials, which have been
called pragmatic, large-scale, or public health trials, are tools
to evaluate the applicability of a treatment in a wider setting,
to observe uncommon adverse events, and to identify factors
influencing the main outcomes and risks (Table 1).9 To
maximize the external validity, or generalizability, effective-
ness trials are conducted under naturalistic circumstances in
clinical practice settings. Heterogeneous patients selected
based on nonstringent eligibility criteria receive the broadly
defined treatment without close monitoring or supervision
with corrective feedback. The range of the heterogeneity
should be as wide as that seen in clinical practice. Inclusion
of atypical patients and those with comorbidities will ensure
that patients to whom the treatment will be given in the
clinical setting will be represented. Large-scale trials may fail
to detect a benefit in a population mixed with groups of
patients that benefit from the treatment and other groups in
which the treatment has no effect or is harmful. It is thus
essential to study factors predictive of the treatment effect
and to have enough power to perform them. It is very
important to identify the population of patients that benefits
from the treatment.
The use of stratification is only to improve the power of
the analysis and to limit bias in the comparison of subgroups,
but not to avoid imbalance in prognostic factors as they are
balanced in large trials. The follow-up period is often longer
in effectiveness trials.
Although the study design used is often still that of a
RCT for these trials, single-arm cohort studies may also be
equally, and even sometimes more, appropriate.
HYPOTHESIS AND STUDY DESIGN OF
EFFECTIVENESS TRIALS
In contrast to efficacy trials, of which the RCT is
widely accepted as the standard procedure, the nature of what
constitutes sound effectiveness trials is much less clear, and a
few study designs have been tried according to their purpose.
The hypothesis to be examined in effectiveness trials is the
reproducibility of the results of an efficacy trial conducted
under a controlled environment in the clinical practice set-
ting. To confirm a hypothesis verified in an efficacy trial that
“Treatment A” is better than “Treatment B,” an RCT design
may also be required in the subsequent effectiveness trials.
Several confounding factors should be stratified at random-
ization, and the sample size may need to be larger than that in
the relevant efficacy trial to detect small significant differ-
TABLE 1. General Characteristics of Efficacy and Effectiveness Trials
Characteristics Efficacy (Explanatory) Trials Effectiveness (Pragmatic) Trials
Need To understand a therapeutic process To make clinical decisions
Purpose To demonstrate the efficacy in as short a time
aspossible
To assess risk, effectiveness, and cost-effectiveness; to
identify influencing factors
Focus of inference Internal validity External validity, generalizability
Setting Highly controlled and specificclinical research setting Less controlled and representativeclinical practice setting
Design RCTs Cohort studies or RCTs
Treatment Clearly defined, manual based Broadly defined, easily adaptable to the practice setting
Eligibility criteria Strict Relaxed
Study population Homogeneous Heterogeneous
No. of patients 1000 1000–10,000
Monitoring Close supervision with corrective feedback Not close
Data Complex and detailed Simple
Clinician Rigorously trained Variable level of training
Institute Academic hospital Community hospital
RCTs, randomized controlled trials. Adapted from Nash JM, McCrory D, Nicholson RA, Efficacy and effectiveness approaches in behavioral treatment trials. Headache
2005;45:507–512 and Piantadosi S . Clinical Trials. New York: John Wiley & Sons, Inc., 1997.
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ences in a heterogeneous patient population. In contrast, to
confirm the efficacy of “Treatment A,” such as the response
and survival obtained in an efficacy trial, a prospective,
single-arm cohort design may be adequate for the subsequent
effectiveness trial. Diversity in patient population and setting
should be enhanced by using practice-oriented protocols to
reduce barriers to participation to identify prognostic factors.
The primary end point in these trials, for example, the 2-year
survival rate, should be evaluated in subset groups of patients
categorized by prognostic factors as well as in a whole
population. Because of its higher potential for bias than
RTCs, detailed description of the cohort constitution and of
the patients excluded from it should be included.
A meta-analysis of large RCTs with long-term fol-
low-up can be used to evaluate harmful effects, but are not
optimal to detect rare toxicities. To study acute and late toxic
effects, several designs are possible: prospective cohorts,
health insurance/claim databases, and cancer registries. Pro-
spective cohort studies of combination chemotherapy and
combined modality therapy are good candidates for investi-
gator-initiated trials. In the framework of the new drug
development, the efficacy and effectiveness are evaluated
mainly in phase III and IV trials, respectively. Phase IV trials
are conducted after obtaining approval for the drug use to
monitor the safety and effectiveness in the general popula-
tion. Rare, but life-threatening adverse events of a drug (e.g.,
interstitial lung disease [ILD]) or a combination of drugs
(e.g., combination of the antiviral agent sorivudine and oral
fluorouracil analogues) may be identified in this phase.10,11
The Ministry of Health, Labor, and Welfare of Japan recently
approved some new drugs on the condition that their toxicity
is prospectively surveyed in the clinical setting. These in-
clude leflunomide, a newly developed disease-modifying an-
tirheumatic drug that exhibits anti-inflammatory, antiprolif-
erative, and immunosuppressive effects, and oxaliplatin for
colorectal cancer. According to a recent report of a prospec-
tive postmarketing surveillance, of 5506 patients receiving
leflunomide between August of 2003 and July of 2005, 76
patients (1.4%) had suspected ILD and 25 died of it, whereas
the incidence of ILD associated with leflunomide reported
from outside Japan is only 0.02%.12 This high frequency of
ILD among Japanese patients was revealed only by an effec-
tiveness trial.
EFFECTIVENESS TRIALS RELATED TO LUNG
CANCER TREATMENT (TABLE 2)
Gefitinib is an orally available, selective epidermal
growth factor receptor tyrosine kinase inhibitor that has been
shown to exert antitumor activity in patients with previously
treated advanced non-small cell lung cancer (NSCLC). The
safety and tolerability of gefitinib have been established in
four open-label, multicenter, phase I dose-escalation studies
and two multicenter, randomized phase II studies. After this
drug was marketed in Japan, however, an unexpectedly high
incidence of ILD, as high as 5%, was noted in subjects treated
with the drug.10,13 A prospective survey of gefitinib toxicity
in 3354 patients with NSCLC treated at 698 hospitals in
Japan between June and December of 2003 showed that the
incidence of ILD was 5.8% and the mortality was 2.5%. This
study also disclosed risk factors for the development of ILD
in the Japanese population, including preexisting pulmonary
fibrosis, smoking history, and poor performance status.14 This
is an example of the importance of an effectiveness trial for
lung cancer treatment.
Bevacizumab, a humanized monoclonal antibody that
inhibits vascular endothelial growth factor, has been shown to
improve survival when given together with chemotherapy in
patients with advanced nonsquamous NSCLC. However,
grade 3/4 bleeding from the primary site, central nervous
system, gastrointestinal tract, and other organs was noted in
4.5% of patients receiving the drug in a phase III study.15
These new types of treatment agents with previously uncom-
mon life-threatening toxicity are also considered important
areas for effectiveness trials.
Another subject for effectiveness trials may be chemo-
radiotherapy for locally advanced lung cancer because the
superiority of the concurrent over the sequential approach
TABLE 2. Important Areas Related to Lung Cancer Treatment for Effectiveness Trials
Therapy Subject Population Toxicity Incidence
New agent with life-threatening toxicity
EGFR inhibitors Advanced NSCLC Pneumonitis 1%–5%
VEGF inhibitors Advanced NSCLC Bleeding 5%
Intensive therapy with life-threatening toxicity
Chemoradiotherapy Stage III NSCLC Pneumonitis 1%–4%
Limited SCLC Septic shock 1%
Intensive chemotherapy Extensive SCLC Septic shock 1%–2%
Treatment that requires long-term follow-up
Adjuvant chemotherapy Stage IB–IIIA NSCLC Secondary malignancy Rare
PCI Limited SCLC Neurocognitive disturbance Rare
Treatment for heterogeneous populations
Chemotherapy for the elderly Advanced SCLC, NSCLC Depends on general condition
EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PCI, prophylactic cranial irradiation; SCLC, small-cell lung cancer; VEGF, vascular endothelial
growth factor.
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was demonstrated only in patients in good general condi-
tion.16,17 How widely applicable concurrent chemoradiother-
apy is in the general patient population remains unknown. In
addition, evaluation of late toxicities, including secondary
malignancies related to smoking and treatment, and neuro-
cognitive disturbance associated with prophylactic cranial
irradiation has become more important as more long-term
survivors are expected among these patients.18,19
Large-scale RCTs in patients with completely resected
stage I–IIIA NSCLC aimed to confirm the effect of cisplatin-
based adjuvant chemotherapy suggested by the meta-analysis
in 1995.20,21 Only effectiveness trials with long-term fol-
low-up give reliable information as to secondary malignancy
and noncancer related deaths in these patients.
Treatment of elderly patients with lung cancer is also an
important field of effectiveness trials because many of these
patients have comorbidity and decreased organ function, and,
consequently, their general condition varies greatly from one
patient to another.22 There is a debate between those who
promote age-unspecified large-scale trials with an analysis of
the treatment effect according to age as a covariate and those
who promote series of trials limited to an elderly popula-
tion.23,24 The outcome of the former trials can be generalized
only to a small segment of the elderly population who meet
the eligibility criteria of trials designed for younger patients,
whereas the outcome of the latter trials depends greatly on the
definition of the eligibility criteria. Confirmation of effective-
ness will be needed in the both types of trials.
INFRASTRUCTURE OF EFFECTIVENESS TRIALS
Development of the appropriate infrastructure for ef-
fectiveness trials, which are conducted using a large number
of patients, sometimes as many as 10,000 patients, is an
urgent task. A central operations office and data coordinating
center can handle many aspects of multi-institutional trials,
including the recruitment of study institutions, randomization
of patients, data collection, data analysis, and quality control.
Clinical trials performed in an area with a cancer registry may
cost less if collecting the events through a cancer registry
without specific follow-up. The difficulty may be more linked
to the construction of a network of general hospitals partici-
pating actively in clinical research.
The extensive research time and considerable cost of
these processes can be reduced with the use of Internet
resources.25 In addition, a study Web site may facilitate
communication among the trial personnel. A study Web site
may also be used for the following tasks: providing informa-
tion to potential participants, study subjects, and investiga-
tors; listing contact information; and centralizing data han-
dling for patient registration, randomization, and data
collection. A news section of the Web site can provide a
progress report concerning the trial status and advertise up-
coming meetings. A “Frequently Asked Questions” section
can provide investigators with answers to common questions
regarding the study protocol, and a download page can be a
means of distributing study materials (protocol, case report
forms, informed consent forms) to participating study cen-
ters.25
The electronic signature capture technology and elec-
tronic data capture system have been developed by several
companies, including Fujitsu and Hitachi in Japan. An Inter-
net clinical trial supporting system is now provided in Japan
by commercial information technology service providers and
the University Hospital Medical Information Network, a
cooperative organization for national medical schools in Ja-
pan, sponsored by the Ministry of Education, Culture, Sci-
ence, Sports, and Technology of Japan.26
Quality control and quality assurance of clinical trials
become more difficult but more important as the numbers of
participating hospitals, contributors, and patients grow. Care-
ful study planning, use of information technology for data
management, and efficient auditing are critical for effective-
ness trials.27,28 In addition, high-quality study conduct begins
with the proper training of all personnel involved in the study.
TRAINING OF CLINICIANS
Efficacy trials are usually conducted by highly trained
and experienced clinicians in academic institutes, including
university-affiliated hospitals, cancer center hospitals, and
central city general hospitals. When clinicians with varying
academic backgrounds and levels of training are expected to
implement new treatments in routine clinical practice at city
hospitals, effective training of these clinicians is essential to
bridge the gap between the research and practice environ-
ments.29 However, passive dissemination of information, in-
cluding via guidelines and didactic lectures, is generally
ineffective in altering practices, irrespective of how important
the issue or how valid the new treatment might be. Instead, it
would seem necessary to use specific strategies to ensure
improvements in common clinical practice, including the use
of computerized decision support systems, educational out-
reach visits, and interactive educational meetings that include
discussions of practice.29 Opportunities for these should be
provided to clinicians who participate in effectiveness trials.
CONCLUSION
Despite the considerable effort expended on efficacy
trials, relatively little attention has been paid to ensure that
the potential benefits of a new therapy are reproduced in
routine clinical situations. Effectiveness trials are an impor-
tant step toward bridging this gap and effectively implement-
ing new therapies established in efficacy trials in clinical
practice.
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